Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Quality boots, weather systems, and field accessories were among the highlights of this year's product launches. Here’s what ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Recent data from the New York Federal Reserve Bank and Equifax (NYSE:EFX) highlight a troubling trend in U.S. consumer ...

Reports of inadequate liquidity have been greatly exaggerated, but the high-volatility environment in the first six months of ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Akero Therapeutics Inc. research and ratings by Barron's. View 1AKRO revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.